— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
Key highlights from Adobe (ADBE) Q2 2021 earnings results
Adobe Systems Incorporated (NASDAQ: ADBE) reported second quarter 2021 earnings results today. Total revenue grew 23% year-over-year to $3.84 billion. GAAP net income was $1.11 billion, or $2.32 per share,
Three factors that bode well for Delta Air Lines (DAL) going forward
Shares of Delta Air Lines Inc. (NYSE: DAL) have gained 45% over the past 12 months and 11% since the beginning of this year. After a particularly distressful period, like
KR Earnings: All you need to know about Kroger Q1 2021 earnings results
The Kroger Co. (NYSE: KR) reported first-quarter 2021 earnings results today. Total company sales were $41.3 billion compared to $41.5 billion in the same period last year. Excluding fuel, sales
